INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL

Author(s):Show less -

Ramos, Marcus Fernando Kodama Pertille ; Pereira, Marina Alessandra ; Charruf, Amir Zeide ; Victor, Carolina Ribeiro ; Gregorio, Joao Vitor Antunes Marques ; Alban, Luciana Bastos Valente ; Moniz, Camila Motta Venchiarutti ; Zilberstein, Bruno ; De Mello, Evandro Sobroza ; Hoff, Paulo Marcelo Gehm ; Junior, Ulysses Ribeiro ; Dias, Andre Roncon

• Document type: Journal article
• Source: ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY; v. 36, p. 7-pg., 2023-01-01.

Abstract

Background:<bold> </bold>Peritoneal carcinomatosis in gastric cancer is considered a fatal disease, without expectation of definitive cure. As systemic chemotherapy is not sufficient to contain the disease, a multimodal approach associating intraperitoneal chemotherapy with surgery may represent an alternative for these cases.Aims: The aim of this study was to investigate the role of intraperitoneal chemotherapy in stage IV gastric cancer patients with peritoneal metastasis.Methods:<bold> </bold>This study is a single institutional single-arm prospective clinical trial phase II (NCT05541146). Patients with the following inclusion criteria undergo implantation of a peritoneal catheter for intraperitoneal chemotherapy: Stage IV gastric adenocarcinoma; age 18-75 years; Peritoneal carcinomatosis with peritoneal cancer index<12; Eastern Cooperative Oncology Group 0/1; good clinical status; and lab exams within normal limits. The study protocol consists of four cycles of intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy. After treatment, patients with peritoneal response assessed by staging laparoscopy undergo conversion gastrectomy.Results:<bold> </bold>The primary outcome is the rate of complete peritoneal response. Progression-free and overall survivals are other outcomes evaluated. The study started in July 2022, and patients will be screened for inclusion until 30 are enrolled.Conclusions: Therapies for advanced gastric cancer patients have been evaluated in clinical trials but without success in patients with peritoneal metastasis. The treatment proposed in this trial can be promising, with easy catheter implantation and ambulatory intraperitoneal chemotherapy regime. Verifying the efficacy and safety of paclitaxel with systemic chemotherapy is an important progress that this study intends to investigate. (AU)

• FAPESP's process: 20/13249-0 - Evaluation of intraperitoneal chemotherapy in treatment of gastric cancer in patients with peritoneal carcinomatosis
• Grantee: André Roncon Dias
• Support Opportunities: Regular Research Grants